Table 4.
Cox proportional hazard models for cardiac death (A) and all cause mortality (B).
|
|
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| A - Cardiovascular Death | B - All Cause Mortality | |||||||||
| Global R2= 0.48 - Haller’s C=0.79±0.02
|
Global R2= 0.45 - Haller’s C=0.77±0.02
|
|||||||||
| Hazard Ratio | P | Percent fraction of global R2 (%) | Bootstrap Inclusion Frequency (%) | Linearity Stability (%) | Hazard Ratio | P | Percent fraction of global R2 (%) | Bootstrap Inclusion Frequency (%) | Linearity Stability (%) | |
|
|
|
|||||||||
| Age (10 years) | 1.51 | 0.001 | 17.5% | 78.6% | 76.30% | 1.41 | 0.002 | 15.9% | 80.0% | 82.00% |
| Gender | 0.96 | 0.86 | NA | 13.5% | NA | 1.09 | 0.67 | NA | 7.3% | NA |
| LVEF (5% units) | 0.86 | 0.03 | 13.2% | 62.2% | 87.60% | 0.83 | 0.003 | 19.3% | 76.1% | 91.30% |
| NYHA | 2.45 | 0.02 | 8.7% | 62.7% | NA | 1.56 | 0.12 | NA | 40.2% | NA |
| ln NTpro-BNP (IQ units) | 2.23 | ≤ 0.0001 | 27.5% | 95.7% | 97.7% * | 2.05 | ≤ 0.0001 | 29.6% | 96.2% | 99.2% * |
| ln GRK2 (IQ units) | 2.01 | ≤ 0.0001 | 18.9% | 89.1% | 85.8% * | 1.94 | ≤ 0.0001 | 21.7% | 98.1% | 75.9% * |
| Norepinephrine | 0.90 | 0.53 | NA | 53.5% | NA | 0.99 | 0.40 | NA | 26.4% | NA |
| Systolic Blood Pressure | 1.01 | 0.13 | NA | 29.4% | NA | 1.01 | 0.11 | NA | 46.5% | NA |
| Resting heart rate | 1 | 0.08 | NA | 4.3% | NA | 1.00 | 0.99 | NA | 3.0% | NA |
| LBBB | 0.89 | 0.67 | NA | 15.2% | NA | 0.80 | 0.68 | NA | 14.3% | NA |
| Low serum sodium | 1.69 | 0.06 | NA | 55.0% | NA | 1.41 | 0.39 | NA | 35.6% | NA |
| Low serum cholesterol | 1.41 | 0.32 | NA | 16.4% | NA | 1.12 | 0.94 | NA | 11.3% | NA |
| Hyperruricemia | 0.89 | 0.64 | NA | 19.3% | NA | 0.78 | 0.56 | NA | 20.1% | NA |
| Comorbidity | ||||||||||
| Diabetes | 1.16 | 0.46 | NA | 24.3% | NA | 1.10 | 0.59 | NA | 24.5% | NA |
| Hypertension | 0.87 | 0.60 | NA | 28.8% | NA | 0.86 | 0.48 | NA | 40.5% | NA |
| COPD | 1.81 | 0.008 | 3.0% | 73.7% | NA | 1.94 | 0.001 | 4.8% | 84.0% | NA |
| CKD | 1.86 | 0.003 | 11.4% | 70.3% | NA | 1.54 | 0.02 | 8.8% | 60.7% | NA |
| Drugs | ||||||||||
| ACE-I ARBs | 1.61 | 0.14 | NA | 55.6% | NA | 1.15 | 0.56 | NA | 17.9% | NA |
| Beta Blockers | 0.87 | 0.55 | NA | 16.8% | NA | 0.97 | 0.88 | NA | 9.0% | NA |
|
|
|
|||||||||
*
Linearity stability for NTpro-BNP and GRK2 refers to the stability of the logarithm form of these factors.
Abbreviations: NA= not applicable, IQ= interquartile (25°<->75° percentile), COPD= chronic obstructive pulmonary disease, LVEF= left ventricular ejection fraction, NYHA= New York Heart Association, CKD= chronic kidney disease (glomerular filtration rate ≤ 50ml/min), ACE-I= angiotensin-converting-enzyme inhibitor, ARBs= angiotensin receptor blockers, LBBB=left bundle branch block. Bold face= statistically significant factors.